Despite Medicare coverage, many cancer patients still do not receive testing that guides treatment options
While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georg
<p>While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georg</p>